The Chronic Spontaneous Urticaria (CSU) market is rapidly evolving as innovative therapies and improved diagnostic techniques gain momentum in 2025. This growth phase is fueled by increasing clinical awareness, rising prevalence, and ongoing pharmaceutical investments addressing unmet medical needs. Industry dynamics are being reshaped by emerging